What happened with BIIB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Biogen supplies medicines to patients with neurological and other serious diseases. Multiple-sclerosis medicines make up its largest product business, with TYSABRI an important seller; rare-disease treatments are next, led by SPINRAZA for spinal muscular atrophy. Most revenue comes from product sales. In the United States, Biogen sells mainly through drug wholesalers, specialty distributors and specialty pharmacies. Two wholesalers account for a large share of product sales, making them important customers.
Biogen also earns substantial revenue from medicines marketed and distributed by Roche under its Genentech collaboration. It receives royalties on OCREVUS sales and a share of U.S. profits from RITUXAN, GAZYVA and LUNSUMIO, so this income depends on Roche’s sales rather than Biogen’s own distribution. Its collaboration with Eisai also gives it a share of the commercial proceeds from LEQEMBI for Alzheimer’s disease, after shared product costs.
Sales depend on government health programs and private insurers covering treatments and agreeing to prices and reimbursement. Generic competition has already substantially reduced TECFIDERA revenue. Drug regulation also limits how Biogen promotes and distributes medicines, and its manufacturing operations must meet regulatory quality requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Biogen’s results also hinge on Roche/Genentech, whose collaborations generated 18.8% of its 2025 revenue, and Eisai, its partner in expanding LEQEMBI sales.
Ionis Pharmaceuticals licenses SPINRAZA and QALSODY to Biogen for worldwide commercialization, so demand for these medicines connects their results; Biogen pays Ionis 11%–15% of annual worldwide SPINRAZA net sales as royalties. Ionis’s SPINRAZA royalty revenue is therefore a useful read on that Biogen rare-disease business.
Novartis competes for the same patients as Biogen: its Kesimpta and other multiple sclerosis medicines rival Biogen’s MS portfolio, while its spinal muscular atrophy gene therapies compete with SPINRAZA.
Eli Lilly’s Kisunla competes directly with Biogen and Eisai’s LEQEMBI to treat Alzheimer’s disease by targeting amyloid and changing the disease’s course. Watch Kisunla’s safety, effectiveness, convenience and cost-effectiveness, the factors cited as shaping competition in these treatments.
Alkermes licenses the multiple sclerosis medicine VUMERITY to Biogen and receives a 15% royalty on worldwide net sales, tying its income to Biogen’s sales of the drug. Biogen supplied about 9% of Alkermes’s 2025 revenue; VUMERITY royalties are the line to watch for this growing part of Biogen’s MS business.
Supernus Pharmaceuticals and Biogen share equally in U.S. operating profits and losses from ZURZUVAE, the postpartum depression medicine they jointly commercialize, with Biogen recording the sales. Watch U.S. patient numbers: their increase drove ZURZUVAE’s 2025 revenue growth.
Sanofi competes with Biogen for multiple sclerosis patients through Aubagio and Lemtrada; its MS drug-development programs could also change future treatment choices.
Bristol Myers Squibb’s Zeposia competes for multiple sclerosis patients with Biogen’s broad MS medicine portfolio.
Biogen depends on Stoke Therapeutics’s development of zorevunersen, an investigational Dravet syndrome treatment that Biogen has exclusive rights to commercialize outside the United States, Canada and Mexico. Watch Stoke’s clinical and regulatory progress; Biogen shares development costs and would pay royalties on future licensed-product sales.
Denali Therapeutics and Biogen share the development prospects of BIIB122/DNL151, an investigational Parkinson’s disease medicine they plan to commercialize together, with Biogen potentially owing Denali milestone payments. Watch Biogen’s LUMA study in early-stage Parkinson’s and Denali’s BEACON study in patients with confirmed pathogenic LRRK2 variants.
Viatris’s generic dimethyl fumarate in Europe competes directly with Biogen’s TECFIDERA, whose revenue has been hurt by deeply discounted generics. Watch Viatris’s European sales and exclusivity litigation: it says it resumed selling the generic under a new authorization, while Biogen is seeking damages in ten European countries.
Royalty Pharma receives a share of sales from both Biogen’s TYSABRI and Evrysdi, which competes with Biogen’s SPINRAZA, while also helping fund Biogen’s litifilimab development. Its TYSABRI royalty receipts offer a sales-based read on Biogen’s MS medicine, rather than on its profits.
Scholar Rock’s investigational apitegromab is intended to treat muscles in spinal muscular atrophy patients already receiving treatments such as Biogen’s SPINRAZA, rather than simply replace those medicines. Watch its clinical and approval progress for this existing treated patient group.
C4 Therapeutics supplies Biogen with licensed technology and drug candidates designed to remove target proteins, and Biogen pays milestones as candidates advance clinically. Its payments for BIIB142 entering the clinic in September 2025 and BIIB129 entering Phase 1 in January 2026 mark concrete progress in Biogen’s licensed pipeline.
Novartis AG earningsNVS
Novartis’s report will show how strongly its multiple-sclerosis medicines compete with Biogen for patients.
Look at sales and demand for Novartis’s multiple-sclerosis medicines. Strong demand would show that Novartis is winning interest among patients Biogen also serves, raising competitive pressure on Biogen’s MS business; weak demand would point to less pressure from this rival.
Biogen Inc. earningsThis company
Biogen’s report will show whether rare-disease therapies are bringing in enough revenue to offset pressure on its multiple-sclerosis business.
Read rare-disease product revenue alongside multiple-sclerosis product revenue. Rare-disease growth with MS revenue stabilizing would show that newer therapies are broadening Biogen’s business; rare-disease growth with further MS declines would show that new products are still filling a hole left by the older franchise.
Alkermes Inc. plc earningsALKS
Alkermes’s VUMERITY royalties will offer a direct read on Biogen’s sales of the drug and the royalty expense those sales generate.
Look for Alkermes’s VUMERITY royalty revenue and its explanation of product sales. Higher royalties mean stronger sales for Biogen’s drug, but also a larger royalty expense; lower royalties point to a smaller sales stream and less royalty expense.
Fed Interest Rate Decision
For Biogen, the Fed’s decision on short-term interest rates matters mainly through the cost of new borrowing or refinancing its outstanding notes, not through a filing-identified driver of current sales or costs.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could make future borrowing or refinancing more expensive for Biogen, though it had no borrowings under its revolving credit facility and no near-term debt maturities.
If it comes in below expectations
Lower rates could make future borrowing or refinancing cheaper for Biogen, though it had no borrowings under its revolving credit facility and no near-term debt maturities.
Eli Lilly & Co. earningsLLY
Lilly’s report will show how demand for Kisunla, a rival Alzheimer’s treatment, may shape competition for Biogen and Eisai’s LEQEMBI.
Look for Lilly’s account of Kisunla sales and patient uptake. Growing sales and faster uptake would mean stronger competition as Biogen and Eisai seek patients for LEQEMBI; weak sales or uptake would mean less pressure from this rival, not proof of LEQEMBI demand.
Supernus Pharmaceuticals, Inc. earningsSUPN
Supernus Pharmaceuticals’s report will show whether U.S. growth in ZURZUVAE patients is translating into stronger operating profits shared with Biogen.
Read changes in U.S. ZURZUVAE patient numbers alongside the operating profits Biogen and Supernus share. More patients with higher profits would show that demand is becoming income for Biogen; more patients without profit growth would mean sales are not yet translating into a stronger shared return.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis Pharmaceuticals’s SPINRAZA royalties will provide a read on sales of Biogen’s rare-disease medicine and the royalty cost tied to them.
Look for Ionis’s SPINRAZA royalty revenue and related sales commentary. Higher royalties point to stronger demand for Biogen’s drug, but also a larger royalty cost for Biogen; lower royalties point to weaker sales and a smaller royalty burden.
Royalty Pharma plc earningsRPRX
Royalty Pharma’s TYSABRI receipts offer a sales-based read on Biogen’s multiple-sclerosis drug, not on its profit.
Look for Royalty Pharma’s TYSABRI receipts. Higher receipts point to stronger sales of Biogen’s drug, but also more royalties paid by Biogen; lower receipts point to weaker sales and a smaller royalty expense. This is a read on TYSABRI, not Biogen’s whole MS business.
Viatris Inc. earningsVTRS
Viatris’s report will show how its European generic dimethyl fumarate competes with Biogen’s TECFIDERA on sales.
Look for Viatris’s account of European generic dimethyl fumarate sales and authorization. Strong sales would show that lower-priced copies are still taking volume from TECFIDERA, increasing pressure on Biogen’s price and sales; weak sales would suggest less immediate pressure, but would not resolve the patent dispute.
